Table 1.

Clinical conditions and diseases were tolperisone was studied.

Clinical condition or disease	Quality of the study	Tolperisone dosage	Reference
Low back pain	B	150–400 mg per day	(Chernysheva and Bagirova 2005)a
			(Vorob'eva and Kozlova 2006)
Post cerebral stroke spasticity	A	300–900 mg per day	(Stamenova et al. 2005)
			(Stamenova et al. 2006)
Spinal pain	C	300 mg	(Parfenov and Batysheva 2003)
Neuropathic diabetic foot syndrome	B	150–400 mg	(Briskin et al. 2000a)
Painful reflex muscle spasm (including cervical and low back pain)	A	300 mg per day	(Pratzel et al. 1996)
Peripheral vascular disease	C	Unknown	(Liubishchev 1967)
			(Sztankay 1970)
			(Abranyi 1988)
			(Briskin et al. 2000b)
Multiple sclerosis	C	Unknown	(Lashch and Avakian 2000)
Neurolathyrism	A	300 mg per day	(Melka et al. 1997)
Myotonias	C	Unknown	(Abranyi 1988)
Tension headache	C	150–900 mg	(Csanyi 1989)b
			(Solozhenkin 1999)
			(Solovieva et al. 2005)

A: High standard clinical trial, placebo‐controlled, randomized, double blind.

B: Medium standard clinical trial, to some extend placebo‐controlled and randomized.

C: Low standard clinical trial, no placebo‐controlled, not randomized, not blinded, case studies

^aNo abstract available.

^bReview.